Prostate Cancer: Symptoms, Causes, Diagnosis & Treatment

Prostate cancer designates malignant neoplasia of the prostatic acinar–ductal epithelium, with the great majority being adenocarcinoma originating in the peripheral zone where biopsy needles and digital examination preferentially sample. Rarer histologic variants—ductal, mucinous, signet-ring, intraductal, neuroendocrine and small-cell—follow distinct natural histories: small-cell and neuroendocrine differentiation often arise after prolonged androgen-receptor blockade and behave like aggressive visceral disease rather than typical bone-tropic adenocarcinoma.

Biologically the disease ranges from clinically insignificant low-grade lesions that may never threaten survival to high-grade tumours with rapid lymphatic, perineural and osteoblastic skeletal spread. Androgen-receptor signalling is central, which is why testosterone suppression remains the backbone of advanced therapy and why escape from castration (mCRPC) defines the inflection point between hormone-sensitive ladders and second-line oncology pathways. Nurses anchor communication by separating the “overdiagnosis worry” around Grade Group 1 disease from the genuine urgency of high-grade or metastatic presentations, and by framing surveillance pathways as active rather than passive.

Pathology, PSA and TNM staging combine into risk groups that drive whether a man enters surveillance, undergoes definitive local therapy or starts systemic treatment. Reporting uses the contemporary ISUP grade-group system (a five-tier translation of Gleason scores) plus NCCN/EAU/D’Amico risk strata. Clinical letters and MDT minutes should print the band so bedside teams do not back-derive from memory.

↔Narrow widths: swipe sideways for ISUP grade-group reference.

Risk tier shorthand (D’Amico/NCCN family)

• Very low / low risk: PSA <10 ng/mL, Grade Group 1, cT1c–T2a, limited core involvement—active surveillance is usually first-line in fit men.
• Intermediate risk: PSA 10–20 ng/mL or Grade Group 2–3 or cT2b—subclassified favourable vs unfavourable; decisions hinge on percentage of cores, PSA density and patient priorities.
• High / very high risk: PSA >20 ng/mL or Grade Group 4–5 or cT2c+/T3–T4—definitive radiotherapy with 18–36 months of ADT, or radical prostatectomy with pelvic lymphadenectomy and risk-adapted adjuvants.
• Metastatic: Nodal (N1) or distant (M1)—systemic backbone with ADT plus an ARPI and/or docetaxel; local therapy considered selectively (e.g., low-volume M1).

Most localised prostate cancer is asymptomatic at diagnosis and detected via a PSA conversation or incidental finding. When lower urinary tract symptoms appear they overlap heavily with benign prostatic hyperplasia—frequent urination, hesitancy, nocturia, weak stream and post-void dribbling are non-specific. Distinct features of malignancy tend to emerge later: gross or microscopic blood in urine, haematospermia, new erectile dysfunction in a man without vascular risk drivers, and—worryingly—skeletal pain or unexplained weight loss suggesting metastatic burden.

High-yield presentation clusters

• Asymptomatic PSA elevation flagged on opportunistic screening or work-up of urinary incontinence review.
• Hard, asymmetric or nodular prostate on examination—pathology rarely mimics this exactly even when PSA is borderline.
• Mechanical bladder outlet flare driven by tumour mass effect, which can coexist with BPH without being explained by it.
• Bone metastasis presentation: deep back pain worse at night, ribs/pelvis tenderness or pathological fracture.
• Profound fatigue, anaemia or unilateral lower-limb oedema from pelvic nodal mass.

Aetiology is multifactorial. Age dominates—incidence rises sharply after 50 and steeply after 65. Ancestry effects are real: men of Black African and African-Caribbean heritage face higher incidence and tend to present at younger ages and with more aggressive biology, although access and screening behaviour also contribute. Germline pathogenic variants in BRCA2 (and to a lesser extent BRCA1, ATM, CHEK2, MLH1/MSH2/MSH6 Lynch genes) confer higher risk and earlier presentation; these now have therapeutic relevance in advanced disease via PARP inhibitors.

Modifiable amplifiers

• Smoking and central adiposity correlate with more aggressive phenotypes and worse outcomes; address through structured cessation and weight management referrals rather than vague advice.
• Diets dominated by processed and high–saturated-fat patterns sit lower in the evidence pyramid than the genetic and ancestry signals but appear in survivorship counselling.
• Untreated hypogonadism management still requires malignancy exclusion before testosterone replacement, but otherwise endocrine drivers are limited.

Things often misframed as causes

Vasectomy is not an established causal driver in current syntheses; common-or-garden prostatitis is not a malignancy precursor though it skews PSA values; benign prostatic hyperplasia and prostate cancer co-exist by age but BPH is not a precancer.

The contemporary pathway pivots on PSA + digital rectal examination, multiparametric MRI before biopsy in most centres, then targeted ± systematic biopsy (commonly transperineal), with ISUP grading and risk-staged imaging only if disease is confirmed. Premature or unprotected biopsy without imaging risks under-detection of clinically significant disease and over-detection of indolent lesions.

Clinical assessment

• Targeted history: family cancer pattern, ancestry, urinary symptoms, sexual function baseline, bone pain, weight change, performance status.
• Digital rectal examination noting volume, symmetry, induration or nodularity—document the gland rather than skipping the exam in busy clinics.
• Comorbidity mapping for life-expectancy framing—therapy decisions hinge on this as much as on stage.

Laboratory investigations

• Serum PSA (and prior trajectory); avoid the test within 4–6 weeks of catheterisation, vigorous DRE-equivalent manoeuvres, urinary infection, ejaculation in the previous ~48 hours or after BPH/transurethral surgery.
• Serum testosterone at baseline and during ADT to confirm castrate suppression (<50 ng/dL or local cut-off).
• Bone-turnover markers and alkaline phosphatase when skeletal metastasis is suspected; renal function (eGFR) anchors contrast and chemotherapy decisions.
• Urinalysis for haematuria or infection that may both confound PSA and unmask alternative pathology.
• Germline panel (BRCA1/BRCA2, MMR-Lynch and homologous-recombination-repair genes) per BRCA1/BRCA2 genetic testing referral criteria—especially in metastatic, high-risk or young-onset disease.

Imaging and tissue

Multiparametric MRI of the prostate (T2, DWI, DCE) is scored by PI-RADS v2.1. PI-RADS 3–5 prompts biopsy with MRI–ultrasound fusion targeting; PI-RADS 1–2 with reassuring PSA density (e.g., <0.15 ng/mL/cc) may permit deferred biopsy with safety-netting. Transperineal biopsy is increasingly preferred over transrectal owing to lower sepsis risk; ciprofloxacin prophylaxis policies are being curtailed in line with fluoroquinolone-stewardship guidance.

Staging in intermediate–high-risk disease uses pelvic MRI, DEXA for baseline bone health before ADT, technetium bone scan or modern PSMA PET (now standard in many systems for high-risk and biochemical recurrence), and CT when nodal or visceral disease is suspected and PSMA PET is unavailable. Standard ultrasound may detect hydronephrosis when locally advanced disease obstructs the ureters.

Separate benign mimics from genuine malignancy when faced with abnormal PSA, lower urinary tract symptoms or a suspicious DRE. Each alternative still warrants a clean diagnostic plan rather than reflex reassurance.

↔Narrow widths: swipe sideways for differential cues.

Localised disease — first-line, by risk

• Very low / low risk: Active surveillance with serial PSA (3–6-monthly initially), repeat mpMRI and confirmatory biopsy at defined intervals; reclassification triggers conversion to definitive therapy. Watchful waiting (lighter follow-up for limited life-expectancy) is distinct and palliation-oriented.
• Favourable intermediate: Active surveillance in selected men, otherwise radical prostatectomy (open, laparoscopic or robot-assisted) or external-beam radiotherapy (EBRT) ± brachytherapy boost—neoadjuvant ADT not routine in this band.
• Unfavourable intermediate / high / very high: Definitive radiotherapy with short-course (~4–6 months) ADT in unfavourable intermediate, escalating to 18–36 months for high-risk; alternatively radical prostatectomy + pelvic lymph-node dissection with risk-adapted adjuvants. Brachytherapy boost may enhance biochemical control in selected high-risk cases.

Metastatic hormone-sensitive disease (mHSPC)

The backbone is androgen deprivation—LHRH agonists (leuprolide, goserelin, triptorelin), an LHRH antagonist (degarelix) when rapid testosterone fall or testosterone-flare avoidance matters, or the oral GnRH antagonist relugolix with a cleaner cardiovascular signal in selected men. Modern practice layers an ARPI (abiraterone + low-dose prednisone, enzalutamide, apalutamide) and/or docetaxel onto ADT—“triplet therapy” (ADT + ARPI + docetaxel) is now standard in high-volume mHSPC in many guidelines.

Castration-resistant disease (mCRPC)

• If not previously exposed, an ARPI (abiraterone or enzalutamide) is typical first-line; sequencing the alternative is generally unhelpful once cross-resistance kicks in.
• Docetaxel chemotherapy is offered to fit men; cabazitaxel follows docetaxel progression.
• Radium-223 alpha-emitter for symptomatic bone-predominant disease without visceral metastases.
• 177Lu-PSMA-617 (radioligand therapy) for PSMA-positive mCRPC after at least one ARPI and a taxane in many systems.
• PARP inhibitors (e.g., olaparib) for tumours with deleterious BRCA1/BRCA2 or other homologous-recombination-repair alterations.
• Pembrolizumab in MSI-H/dMMR or high tumour-mutation-burden disease; sipuleucel-T in selected asymptomatic minimally symptomatic mCRPC where available.

ADT toxicity bundle (clinician-facing)

↔Narrow widths: swipe sideways for ADT toxicity grid.

Monitoring cadence

• Active surveillance: PSA every 3–6 months in the first 2 years then 6-monthly; DRE annually; repeat mpMRI and confirmatory biopsy per protocol (commonly within 12–18 months, then risk-adapted).
• Post-prostatectomy: PSA at 6 weeks and 3-monthly for the first year, then 6-monthly to year 5—a persistently detectable PSA (≥0.1–0.2 ng/mL) or rising trend triggers recurrence work-up.
• Post-radiotherapy: PSA nadir typically reached 18–36 months out; biochemical failure defined by nadir + 2 ng/mL (Phoenix criteria) prompts restaging.
• ADT on initiation: testosterone confirmation at ~3–4 weeks, baseline DEXA, lipids, HbA1c, ECG when QT-relevant agents added; BP and weight every clinic visit.
• Bone-metastatic surveillance: alkaline phosphatase, calcium, vitamin D; symptom-driven imaging plus 6–12-monthly cross-sectional review per response.

Medication choreography

• Time LHRH agonist injections with anti-androgen cover (e.g., bicalutamide for 2–4 weeks) when testosterone-flare risk matters (high-volume disease, MSCC risk).
• Symptomatic outlet management may include tamsulosin alpha-blockade; finasteride or dutasteride 5-ARI options need careful PSA-interpretation rules (halve raw PSA when on chronic 5-ARI therapy for risk discussion).
• Reinforce that pain control in bone-metastatic disease is multimodal—non-opioid first, structured opioid titration with morphine equivalents and breakthrough plans, palliative radiotherapy for focal pain rather than indefinite opioid escalation.
• Confirm anticoagulation pause protocols around prostatectomy and biopsy windows; document last dose, indication and bridging plan in handover.

Referral & MDT thresholds

• Refer suspected MSCC same day to acute oncology and spinal pathway—do not wait for outpatient slots.
• Genetic counselling referral for men diagnosed under 60, metastatic at presentation, intraductal histology or strong family history (breast/ovarian/pancreatic clusters).
• Survivorship review at 6–12 months post-radical therapy: continence, sexual function, bowel symptoms (after pelvic RT), mental health and cardiometabolic risk.

• Persistent urinary incontinence and stricture after radical prostatectomy; structured pelvic-floor rehabilitation is the cornerstone of management.
• Radiation cystitis and proctitis (acute and late) with rectal bleeding, urgency or stricture after EBRT/brachytherapy.
• Bowel/bladder dysfunction or neurology from untreated MSCC—often irreversible if presentation is late.
• Pathologic fractures and skeletal-related events; hypercalcaemia of malignancy in advanced bone disease.
• Acute urinary retention or obstructive acute kidney injury from large pelvic mass or bilateral ureteric obstruction.
• Treatment-related sepsis (post-biopsy especially), febrile neutropenia on chemotherapy, hypersensitivity reactions to taxanes.
• Mood and cognitive impact on long-term ADT—screen and treat depression and anxiety actively.
• Accelerated bone loss and frank osteoporosis from prolonged hypogonadism.

Primary prevention is limited and largely lifestyle-flavoured: avoid smoking, maintain healthy weight, treat metabolic syndrome aggressively and embed structured physical activity. Chemoprevention with 5-alpha-reductase inhibitors lowers overall prostate cancer detection but does not improve survival and may shift histology toward higher-grade lesions—so they are not endorsed for primary prevention in current major guidelines. The most impactful “prevention” is informed early detection in selected men: shared decision-making about PSA testing typically from age 50 (or 45 in men of Black African ancestry and those with a strong family history), with documented discussion of overdiagnosis and overtreatment trade-offs.

Outcome varies enormously by stage and grade group. Low- and intermediate-risk localised disease frequently carries 10-year cancer-specific survival close to that of age-matched controls, particularly when stratified into surveillance versus radical therapy by biology. High-risk localised disease still achieves durable control with multimodal therapy in many men. Metastatic disease has become a chronic illness for many—median survival has shifted upward with ARPI and triplet strategies, and selected men with low-volume metastatic disease at presentation now anticipate years rather than months. Quality-of-life trade-offs around continence, sexual function and ADT toxicity weigh as much as survival statistics in real-world conversations.

Prostate cancer conversations sit at the intersection of statistics, masculinity and survivorship—rushed or templated language erodes trust. Notice the man who under-reports symptoms, the partner who carries unspoken worry about sexual change, the older patient quietly choosing watchful waiting because he fears the “fix” more than the disease. Translate jargon (Gleason, ISUP, ADT, mCRPC) into everyday language and write it down so it survives clinic exit.

• Document continence pad use, erectile function and bowel symptom scores at each survivorship visit—numbers anchor conversations better than impressions.
• Co-design ADT teaching with partners present where the patient agrees; intimacy planning is part of survivorship, not an optional add-on.
• On the inpatient floor, treat any new neurology in a man with prostate cancer as MSCC until imaging proves otherwise—do not normalise it as “his usual back.”
• Pair fall risk assessment with osteoporosis screening in men on long-term ADT—the combination predicts hip and vertebral fractures more than either alone.

Use nurse-initiated rapid response activation where policy permits, document baseline neurology in case of subsequent dispute, and ensure pain control is concurrent with diagnostics rather than deferred.

NCLEX-style clinical judgment practice (NCSBN Clinical Judgment Measurement Model): recognise cues → analyse cues → prioritise hypotheses → generate solutions → take safe action → evaluate outcomes. Seven Next Generation–style prompts walk through a PSA-triggered work-up, MSCC red flags, ADT-related deterioration, multi-patient triage, an ordered prostate-cancer pathway, a matrix matching grade groups to management emphasis and a counselling cloze on bone health and toxicity surveillance.